EMA Recommends Precautionary Recall of Ecalta, Luminity Batches

The European Medicines Agency recommended a precautionary recall on batches of the Ecalta anti-fungal medicine and the Luminity diagnostic drug after a review of quality assurance at a U.S. manufacturing site.

Doctors are advised to visually inspect vials of Ceplene and Torisel, treatments considered essential for certain cancer patients, before administering the treatments to patients, the EMA said today in a statement on its website.

The London-based regulator last month said it was reviewing shortcomings identified during an inspection of Ben Venue Laboratories’ manufacturing site in Ohio.

To contact the editor responsible for this story: Kristen Hallam at khallam@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.